Abstract
Cancer genetics professionals face a new opportunity and challenge in adapting to the availability of cancer genetic testing panels, now available as a result of Next Generation Sequencing (NGS) technology. While cancer panels have been available for over a year, we believe that there is not yet enough data to create practice guidelines. Despite this, a year of experience allows us to provide our opinion on points to consider as cancer genetic counselors incorporate this testing technology into genetic counseling practice models. NGS technology offers the ability to potentially diagnose hereditary cancer syndromes more efficiently by testing many genes at once for a fraction of what it would cost to test each gene individually. However, there are limitations and additional risks to consider with these tests. Obtaining informed consent for concurrent testing of multiple genes requires that genetics professionals modify their discussions with patients regarding the potential cancer risks and the associated implications to medical management. We propose dividing the genes on each panel into categories that vary by degree of cancer risk (e.g. penetrance of the syndrome) and availability of management guidelines, with the aim to improve patient understanding of the range of information that can come from this testing. The increased risk for identifying variants of uncertain significance (VUS) when testing many genes at once must be discussed with patients. Pretest genetic counseling must also include the possibility to receive unexpected results as well as the potential to receive a result in the absence of related medical management guidelines. It is also important to consider whether a single gene test remains the best testing option for some patients. As panels expand, it is important that documentation reflects exactly which genes have been analyzed for each patient. While this technology holds the promise of more efficient diagnosis for many of our patients, it also comes with new challenges that we must recognize and address.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., et al. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 8(8), 1308–1339. doi:https://doi.org/10.1016/j.hrthm.2011.05.020.
ACMG Board of Directors. (2012). Points to consider in the clinical application of genomic sequencing. Genetics in Medicine, 14(8), 759–761. doi:https://doi.org/10.1038/gim.2012.74.
Ambry Lab. (2013). Retrived from https://doi.org/www.ambrygen.com/sites/default/files/pdfs/ACMG%20shared%20slides.pdf.
Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G., Kelsey, A. M., Harris, M., et al. (2001). Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene, 20(34), 4621–4628. doi:https://doi.org/10.1038/sj.onc.1204621.
Casadei, S., Norquist, B. M., Walsh, T., Stray, S., Mandell, J. B., Lee, M. K., et al. (2011). Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Research, 71(6), 2222–2229. doi:https://doi.org/10.1158/0008-5472.can-10-3958.
Chompret, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., et al. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82(12), 1932–1937. doi:https://doi.org/10.1054/bjoc.2000.1167.
Domchek, S., & Weber, B. L. (2008). Genetic Variants of uncertain significance: flies in the ointment. Journal of Clinical Oncology, 26(1), 16–17. doi:https://doi.org/10.1200/JCO.2007.14.4154.
Domchek, S. M., Bradbury, A., Garber, J. E., Offit, K., & Robson, M. E. (2013). Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? Journal of Clinical Oncology, 31(10), 1267–1270. doi:https://doi.org/10.1200/jco.2012.46.9403.
Erkko, H., Xia, B., Nikkila, J., Schleutker, J., Syrjakoski, K., Mannermaa, A., et al. (2007). A recurrent mutation in PALB2 in Finnish cancer families. Nature, 446(7133), 316–319. doi:https://doi.org/10.1038/nature05609.
Frank, B., Hemminki, K., Meindl, A., Wappenschmidt, B., Sutter, C., Kiechle, M., et al. (2007). BRIP1 (BACH1) variants and familial breast cancer risk: a case–control study. BMC Cancer, 7, 83. doi:https://doi.org/10.1186/1471-2407-7-83.
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., et al. (2009). Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology, 27(8), 1250–1256. doi:https://doi.org/10.1200/jco.2008.16.6959.
Halbert, C. H., Stopfer, J. E., McDonald, J., Weathers, B., Collier, A., Troxel, A. B., et al. (2011). Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women’s concerns? Journal of Clinical Oncology, 29(32), 4302–4306. doi:https://doi.org/10.1200/jco.2010.33.1561.
Hamilton, J. G., Lobel, M., & Moyer, A. (2009). Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychology, 28(4), 510–518. doi:https://doi.org/10.1037/a0014778.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, “Genetic/Familial High-Risk Assessment: Breast and Ovarian,” 2013, https://doi.org/www.nccn.org/index.asp.
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., et al. (2009). Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 324(5924), 217. doi:https://doi.org/10.1126/science.1171202.
Kleihues, P., Schauble, B., Zur Hausen, A., Esteve, J., & Ohgaki, H. (1997). Tumors associated with p53 germline mutations: a synopsis of 91 families. The American Journal of Pathology, 150(1), 1–13.
Lewis, A. G., Flanagan, J., Marsh, A., Pupo, G. M., Mann, G., Spurdle, A. B., et al. (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005–R1016. doi:https://doi.org/10.1186/bcr1336.
Li, F. P., Fraumeni, J. F., Jr., Mulvihill, J. J., Blattner, W. A., Dreyfus, M. G., Tucker, M. A., et al. (1988). A cancer family syndrome in twenty-four kindreds. Cancer Research, 48(18), 5358–5362.
Meldrum, C., Doyle, M. A., & Tothill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. Clinical Biochemistry Reviews, 32(4), 177–195.
Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F., Jr., & Li, F. P. (2001). Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiology, Biomarkers and Prevention, 10(2), 83–87.
Offit, K. (2011). Personalized medicine: new genomics, old lessons. Human Genetics, 130(1), 3–14. doi:https://doi.org/10.1007/s00439-011-1028-3.
Pletcher, B. A., Toriello, H. V., Noblin, S. J., Seaver, L. H., Driscool, D. A., Bennett, R. L., et al. (2007). Indications for genetic referral: a guide for health care professionals. Genetics in Medicine, 9(6), 385–389.
U.S. Preventive Services Task Force (2014). Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: Recommendations From the U.S. Preventive Services Task Force. Annals of Internal Medicine 160 (4), I-16-16.
Rafnar, T., Gudbjartsson, D. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., et al. (2011). Mutations in BRIP1 confer high risk of ovarian cancer. Nature Genetics, 43(11), 1104–1107. doi:https://doi.org/10.1038/ng.955.
Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., et al. (2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics, 39(2), 165–167. doi:https://doi.org/10.1038/ng1959.
Rehm, H. L., Bale, S. J., Bayrak-Toydemir, P., Berg, J. S., Brown, K. K., Deignan, J. L., et al. (2013). ACMG clinical laboratory standards for next-generation sequencing. Genetics in Medicine, 15(9), 733–747. doi:https://doi.org/10.1038/gim.2013.92.
Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901.
Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 38(11), 1239–1241. doi:https://doi.org/10.1038/ng1902.
Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., et al. (2011). Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. The Lancet Oncology, 12(6), 559–567. doi:https://doi.org/10.1016/s1470-2045(11)70119-x.
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108(44), 18032–18037. doi:https://doi.org/10.1073/pnas.1115052108.
Conflict of Interest
Heather Fecteau MS, CGC, Kristen Vogel MS, CGC, Kristen Hanson MS, CGC, and Shannon Morrill-Cornelius MS, CGC declare that they have no conflict of interest.
Human and Animal Rights
No animal or human studies were carried out by the authors for this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fecteau, H., Vogel, K.J., Hanson, K. et al. The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing. J Genet Counsel 23, 633–639 (2014). https://doi.org/10.1007/s10897-014-9714-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10897-014-9714-7